A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

British Journal of Cancer

Volumn 103, Issue 12, 2010, Pages 1783-1787

  Younes, A ^a   Vose, J M ^b   Zelenetz, A D ^c   Smith, M R ^d   Burris, H A ^e   Ansell, S M ^f   Klein, J ^g   Halpern, W ^g,h   Miceli, R ^g   Kumm, E ^g   Fox, N L ^g   Czuczman, M S ⁱ  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f Mayo Clinic   (United States)

^g GLAXOSMITHKLINE   (United States)

^h GENENTECH INC   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apo2L; apoptosis; TRAIL

Indexed keywords

DEATH RECEPTOR 4; MAPATUMUMAB; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BACKACHE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FACE EDEMA; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSOMNIA; LARGE CELL LYMPHOMA; LIMB PAIN; LIVER TOXICITY; LYMPH NODE PAIN; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; NAUSEA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OPEN STUDY; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; STAINING; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT BEARING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECURRENCE;

EID: 78650021203     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605987     Document Type: Article

References (17)

1. Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL (2010) Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). ASCO Meeting Abstracts 28: 8104
2. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17: 1244
3. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A (2005) Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAILR2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 130: 501-510
4. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90
5. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM (2008) A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 14: 3450-3455
6. Humphreys RC, Halpern W (2008) Trail receptors: Targets for cancer therapy. Adv Exp Med Biol 615: 127-158
7. Jin X, Wu XX, Abdel-Muneem Nouh MA, Kakehi Y (2007) Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J Urol 177: 1894-1899
8. Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de Jong S (2003) Expression of TRAIL (TNF-related apoptosisinducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200: 327-335
9. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS (2007) Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13: 4556-4564
10. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le Gouill S, Harousseau JL, Bataille R, Amiot M, Pellat-Deceunynck C (2006) Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2- mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 108: 1346-1352
11. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S (2009) Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study. Clin Cancer Res 15: 5584-5590
12. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, Carrell J, Boyd E, Yao XT, Zhang L, Zhong L, von Kerczek A, Shepard L, Vaughan T, Edwards B, Dobson C, Salcedo T, Albert V (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430-1441
13. Smith MR, Jin F, Joshi I (2007) Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 13: 5528s-5534s
14. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99: 618-624
15. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390-1395
16. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506-512
17. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ (2001) Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: Effects on in vitro hemopoiesis. Blood 98: 3058-3065